CẬP NHẬT về THIẾT kế STENT PHỦ THUỐC

31 511 0
CẬP NHẬT về THIẾT kế STENT PHỦ THUỐC

Đang tải... (xem toàn văn)

Tài liệu hạn chế xem trước, để xem đầy đủ mời bạn chọn Tải xuống

Thông tin tài liệu

CẬP NHẬT VỀ THIẾT KẾ STENT PHỦ THUỐC Assoc. Prof. Truong Quang Binh MD., PhD., FSCAI. University Medical Center 3 [...]... eluting stent with a bioabsorbable polymer An ideal combination of passive and active components The hybrid structure: • * Passive component PROBIO encapsulates the stent, eliminating interaction between the metal stent and the surrounding tissue • * Active component BIOlut contains a bioabsorbable polymer matrix combined with a limus drug for optimal results The underlying PRO-Kinetic Energy Stent System... randomization Orsiro Xience Prime OBJECTIVE To compare the Orsiro stent with a bioabsorbable polymer to the XIENCE Prime® stent with a durable polymer with respect to non-inferiority for instent Late Lumen Loss (LLL) at 9months Clinical follow-up at 1 and 6- months Clinical, angiographic, IVUS* and OCT* follow-up at 9 months PRIMARY ENDPOINT In -Stent Late Lumen Loss at 9-month 20 Orsiro physician presentation,... frequency of in -stent late loss at 9 months (mm) In -stent late lumen loss at 9 months (mm) Orsiro 0.10 ± 0.32 23 Orsiro physician presentation, June 2014 Source: S Windecker, Late breaking trial presentation, EuroPCR 2013 Xience Prime 0.11 ± 0.29 p-value for noninferiority < 0.0001 Angiographic results Orsiro (n=278 Lesions) Diameter stenosis (%) In stent In segment Binary restenosis (%) In stent In segment... Stent apposition by IVUS at 9-month FUP was 100% in both study arms Lesions N = 25 Lesions N = 31 Lesions N = 31 Lesions N = 25 29 Orsiro physician presentation, June 2014 Source: S Windecker, Late breaking trial presentation, EuroPCR 2013 Orsiro performs as best in class   ORSIRO stent (with a bioabsorbable polymer) was non-inferior to the XIENCE Prime stent (with a durable polymer) for the in -stent. .. the treatment of CAD This new technology looks promising and could be the next revolution in interventional cardiology Overview of current DES stent designs Strut and coating thickness in perspective Bioabsorbable Polymer Coated Stent Durable Polymer Coated Stent Abbott/Boston Medtronic Bioabsorbable Scaffold BIOSENSORS Terumo Boston BIOTRONIK Abbott Xience/Promus1 Resolute1 BioMatrix1 Ultimaster1... underlying PRO-Kinetic Energy Stent System provides superior deliverability with stateof-the-art thin strut stent design reducing the long-term risks associated with the presence of a permanent polymer Porous Polymer-free Drug Eluting Stent (polymer-free DES) Porous Polymer-free Drug Eluting Stent (polymer-free DES) Bioresorbable scaffolds (BRS) BRS technology is anticipated not only to eliminate the... Scientific Symposia presentation, TCT 2013 No stent thrombosis at 12 months Small Vessel Subgroup (RVD ≤ 2.75 mm) 30% Orsiro Xience Prime TLF 20% p = 0.2065 10% 12.3% 7.4% Days after PCI 0.0% 0 90 180 270 365 Orsiro 0.13 ± 0.33 Xience Prime 0.15 ± 0.31 P value 0.2025 Cardiac Death2 0.0 1.2 0.1752 Target vessel MI2 2.4 4.4 0.3749 TLR (Clinically driven)2 5.5 6.7 0.7447 In -stent LLL1 1 2 26 Nine-month follow-up... Circumferential 4-7 µm/side Circumferential 3 µm/side Sources:Orsiro physician presentation, June 2014 1: GG Stefanini, M Taniwaki, S Windecker, Coronary stents: novel development, Heart doi:10.1136/heartjnl-2012-303522; 2: IT Meredith, Scientific symposium, TCT 2013 ORSIRO stent (Biotronik) Once implanted into the artery, the BIOlut begins its controlled release of drug  The BIOlute polymer matrix gently breaks... a durable polymer) for the in -stent late loss at 9 months Clinical event rates were low and comparable with both ORSIRO and XIENCE Prime through 9 months Chân thành cảm ơn quý vị DOCTOR ORSIRO stent The other stents ... release of drug  The BIOlute polymer matrix gently breaks down into CO2 and H2O causing minimal tissue burden and avoids inflammation  Following complete absorption of the polymer, only a PROBIO coated stent is left behind  ORSIRO: Late Loss = 0.05 Restenosis = 0% The clinical program for Orsiro is comprehensive and well underway Primary endpoint Status ClinicalTrials.gov Identifier: 30 9 mo LLL Primary . CẬP NHẬT VỀ THIẾT KẾ STENT PHỦ THUỐC Assoc. Prof. Truong Quang Binh MD., PhD., FSCAI. University Medical Center 3

Ngày đăng: 23/08/2015, 07:48

Từ khóa liên quan

Tài liệu cùng người dùng

  • Đang cập nhật ...

Tài liệu liên quan